In vitro COagulation Dynamics of conformational changes in ADAMTS13
- Conditions
- one
- Registration Number
- NL-OMON25418
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
Male
-Age 18-35
Exclusion Criteria
-Participation in a scientific intervention study in the last 3 months
-No informed consent
-History of coagulation disorders
-Active use of prescription medication
-Use of anticoagulant medication, including aspirin
-History of liver disease
-History of chronic transmittable disease
-History of alcohol, smoking or drug abuse
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ROTEM lysis, EXTEM/FIBTEM/ABTEM (i.e. LT, LOT, Li (t), ML, CLR), measured on the day of the blood draw
- Secondary Outcome Measures
Name Time Method ADAMTS13 plasma determinations (antigen, activity, conformation, degradation) <br>Plasma turbidity (time to onset, slope, degree) <br>Whole blood clot lysis, using HALO assay (time to onset, slope, degree), <br>Platelet activation (CD62P, PAC1), using flow cytometry <br>Platelet adhesion and aggregation, using flow model (Time to platelet adhesion, aggregation and breakdown of clots, measured using fluorescent live-cell imaging). <br><br>*There will be only one blood draw (and thus one timepoint) for the volunteer. All outcomes except the ADAMTS plasma determinations. will be measured on the day of thid blood draw. The ADAMTS13 plasma determinations will be performed on a later moment on frozen plasma obtained from the inital blood draw.